

# Marc A Judson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4628302/publications.pdf>

Version: 2024-02-01

289  
papers

17,627  
citations

14655

66  
h-index

16183

124  
g-index

325  
all docs

325  
docs citations

325  
times ranked

10664  
citing authors

#	ARTICLE	IF	CITATIONS
1	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm, 2014, 11, 1304-1323.	0.7	1,077
2	Practice Guidelines for Diseases Caused by Aspergillus. Clinical Infectious Diseases, 2000, 30, 696-709.	5.8	757
3	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosisâ€”State of the Art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases, 2003, 37, S225-S264.	5.8	658
4	Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 795-802.	5.6	629
5	A Case Control Etiologic Study of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1324-1330.	5.6	612
6	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e26-e51.	5.6	521
7	A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. New England Journal of Medicine, 2000, 342, 756-762.	27.0	490
8	Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Systems, 2021, 12, 23-40.e7.	6.2	438
9	A Concise Review of Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 573-581.	5.6	426
10	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clinical Infectious Diseases, 2015, 60, 892-899.	5.8	369
11	Cardiac sarcoidosis. American Heart Journal, 2009, 157, 9-21.	2.7	326
12	Treatment of Sarcoidosis With Infliximab. Chest, 2005, 127, 1064-1071.	0.8	292
13	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 19-27.	0.2	273
14	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal, 2008, 31, 1189-1196.	6.7	271
15	Endobronchial Ultrasound for the Diagnosis of Pulmonary Sarcoidosis. Chest, 2007, 132, 1298-1304.	0.8	257
16	Sarcoidosis in America. Analysis Based on Health Care Use. Annals of the American Thoracic Society, 2016, 13, 1244-1252.	3.2	257
17	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	6.7	248
18	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	9.0	247

#	ARTICLE	IF	CITATIONS
19	Thalidomide for Chronic Sarcoidosis. Chest, 2002, 122, 227-232.	0.8	202
20	The Diagnostic Pathway to Sarcoidosis*. Chest, 2003, 123, 406-412.	0.8	198
21	Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study. Respiratory Medicine, 2010, 104, 717-723.	2.9	180
22	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal, 2014, 44, 1296-1307.	6.7	177
23	Health-Related Quality of Life of Persons With Sarcoidosis. Chest, 2004, 125, 997-1004.	0.8	170
24	The Clinical Features of Sarcoidosis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 63-78.	6.5	167
25	Sarcoidosis: A comprehensive review and update for the dermatologist. Journal of the American Academy of Dermatology, 2012, 66, 699.e1-699.e18.	1.2	161
26	Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1076-1082.	1.1	143
27	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. Clinical Infectious Diseases, 2014, 58, 1219-1226.	5.8	142
28	Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 307-315.	0.5	139
29	The Treatment of Lupus Pernio. Chest, 2009, 135, 468-476.	0.8	139
30	Drug-Induced Sarcoidosis-Like Reactions. Chest, 2018, 154, 664-677.	0.8	131
31	Neurosarcoidosis. Neurologist, 2010, 16, 2-15.	0.7	129
32	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clinical Infectious Diseases, 2018, 66, 1678-1686.	5.8	129
33	The Diagnosis of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 415-427.	2.1	125
34	Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 204-11.	0.2	122
35	Treatment of Corticosteroid-Resistant Neurosarcoidosis With a Short-Course Cyclophosphamide Regimen. Chest, 2003, 124, 2023-2026.	0.8	120
36	Challenges in Cardiac and Pulmonary Sarcoidosis. Journal of the American College of Cardiology, 2020, 76, 1878-1901.	2.8	119

#	ARTICLE	IF	CITATIONS
37	An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids. Chest, 1999, 115, 1158-1165.	0.8	108
38	Sarcoidosis: A comprehensive review and update for the dermatologist. Journal of the American Academy of Dermatology, 2012, 66, 719.e1-719.e10.	1.2	108
39	Extrapulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 083-101.	2.1	107
40	RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF INFlixIMAB IN PATIENTS WITH CHRONIC PULMONARY SARCOIDOSIS. Chest, 2005, 128, 202S.	0.8	106
41	Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes and Immunity, 2005, 6, 509-518.	4.1	106
42	Disease Burden and Variability in Sarcoidosis. Annals of the American Thoracic Society, 2017, 14, S421-S428.	3.2	106
43	The Sarcoidosis Health Questionnaire. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 323-329.	5.6	102
44	Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Medicale, 2012, 41, e331-e348.	1.9	102
45	The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysis. Respiratory Medicine, 2015, 109, 526-531.	2.9	101
46	Pleural Effusions in a Series of 181 Outpatients With Sarcoidosis. Chest, 2006, 129, 1599-1604.	0.8	99
47	Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. Chest, 2009, 136, 526-535.	0.8	98
48	Job and Industry Classifications Associated With Sarcoidosis in a Caseâ€Control Etiologic Study of Sarcoidosis (ACCESS). Journal of Occupational and Environmental Medicine, 2005, 47, 226-234.	1.7	95
49	Efficacy of Short-Course, Low-Dose Corticosteroid Therapy for Acute Pulmonary Sarcoidosis Exacerbations. American Journal of the Medical Sciences, 2010, 339, 1-4.	1.1	93
50	Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis. Archives of Dermatology, 2012, 148, 262.	1.4	90
51	Pathophysiology and clinical management of cardiac sarcoidosis. Nature Reviews Cardiology, 2015, 12, 278-288.	13.7	89
52	Airway Obstruction Arising From Blood Clot. Chest, 1999, 115, 293-300.	0.8	88
53	Spinal Cord Neurosarcoidosis. American Journal of the Medical Sciences, 2014, 347, 195-198.	1.1	84
54	Chronic cutaneous lesions of sarcoidosis. Clinics in Dermatology, 2007, 25, 295-302.	1.6	83

#	ARTICLE	IF	CITATIONS
55	Sarcoidosis: Clinical Presentation, Diagnosis, and Approach to Treatment. American Journal of the Medical Sciences, 2008, 335, 26-33.	1.1	81
56	Cellular Responses to Mycobacterial Antigens Are Present in Bronchoalveolar Lavage Fluid Used in the Diagnosis of Sarcoidosis. Infection and Immunity, 2009, 77, 3740-3748.	2.2	80
57	A Modern Series of Percutaneous Intracavitary Instillation of Amphotericin B for the Treatment of Severe Hemoptysis From Pulmonary Aspergilloma. Chest, 2013, 143, 1414-1421.	0.8	78
58	Biomarkers in sarcoidosis. Expert Review of Clinical Immunology, 2016, 12, 1191-1208.	3.0	77
59	Organizing Pneumonia. American Journal of the Medical Sciences, 2008, 335, 34-39.	1.1	76
60	Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. International Journal of Cardiology, 2017, 227, 565-570.	1.7	76
61	Hepatic, Splenic, and Gastrointestinal Involvement with Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 529-542.	2.1	74
62	A Current Assessment of Rurally Linked Exposures as Potential Risk Factors for Sarcoidosis. Annals of Epidemiology, 2001, 11, 111-117.	1.9	73
63	Sarcoidosis: social predictors of severity at presentation. European Respiratory Journal, 2004, 24, 601-608.	6.7	73
64	Is endosonography guided fine needle aspiration (EUS-FNA) for sarcoidosis as good as we think?. Thorax, 2004, 59, 794-799.	5.6	72
65	Molecular profiling and gene expression analysis in cutaneous sarcoidosis: The role of interleukin-12, interleukin-23, and the AT-helper 17 pathway. Journal of the American Academy of Dermatology, 2012, 66, 901-910.e2.	1.2	71
66	Endobronchial Lesions in HIV-infected Individuals. Chest, 1994, 105, 1314-1323.	0.8	69
67	Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest, 2018, 154, 349-356.	0.8	68
68	Relationship of Environmental Exposures to the Clinical Phenotype of Sarcoidosis. Chest, 2005, 128, 207-215.	0.8	67
69	The treatment of pulmonary sarcoidosis. Respiratory Medicine, 2012, 106, 1351-1361.	2.9	67
70	Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respiriology, 2009, 14, 522-528.	2.3	66
71	Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respiratory Medicine, 2008, 102, 1636-1642.	2.9	61
72	Acute Pulmonary Exacerbations of Sarcoidosis. Chest, 2012, 142, 827-836.	0.8	61

#	ARTICLE	IF	CITATIONS
73	Neurosarcoidosis. Current Treatment Options in Neurology, 2013, 15, 492-504.	1.8	61
74	Endoscopic Ultrasonography with Fine-Needle Aspiration: An Accurate and Simple Diagnostic Modality for Sarcoidosis. Endoscopy, 1999, 31, 377-382.	1.8	57
75	Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 955-964.	5.6	57
76	A New Tool To Assess Sarcoidosis Severity. Chest, 2006, 129, 1234-1245.	0.8	56
77	Cutaneous Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 442-451.	2.1	56
78	Sarcoidosis. Medical Clinics of North America, 2005, 89, 817-828.	2.5	54
79	Racial and Ethnic Disparities in Sarcoidosis: From Genetics to Socioeconomics. Clinics in Chest Medicine, 2006, 27, 453-462.	2.1	54
80	Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 198-204.	0.2	54
81	ICU Admission Muscle and Fat Mass, Survival, and Disability at Discharge. Chest, 2019, 155, 322-330.	0.8	53
82	Neurological Deficits During Treatment With Tumor Necrosis Factor-Alpha Antagonists. American Journal of the Medical Sciences, 2011, 342, 352-355.	1.1	52
83	Allergic Bronchopulmonary Aspergillosis. Clinics in Chest Medicine, 2012, 33, 265-281.	2.1	52
84	Isolated Neurosarcoidosis. Neurologist, 2012, 18, 373-377.	0.7	51
85	Environmental Risk Factors for Sarcoidosis. Frontiers in Immunology, 2020, 11, 1340.	4.8	49
86	Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Design, Development and Therapy, 2013, 7, 325.	4.3	48
87	Validation and Important Differences for the Sarcoidosis Assessment Tool. A New Patient-reported Outcome Measure. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 786-795.	5.6	48
88	Pneumothorax in critically ill patients with COVID-19 infection: Incidence, clinical characteristics and outcomes in a case control multicenter study. Respiratory Medicine, 2021, 184, 106464.	2.9	48
89	Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 147-53.	0.2	48
90	New advances in the management of pulmonary sarcoidosis. BMJ: British Medical Journal, 2019, 367, l5553.	2.3	46

#	ARTICLE	IF	CITATIONS
91	Chronic Facial Sarcoidosis Including Lupus Pernio. American Journal of Clinical Dermatology, 2008, 9, 155-161.	6.7	45
92	Corticosteroids in Sarcoidosis. Rheumatic Disease Clinics of North America, 2016, 42, 119-135.	1.9	45
93	Pleural Effusions Following Lung Transplantation. Chest, 1996, 109, 1190-1194.	0.8	44
94	Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis. Vaccine Journal, 2011, 18, 931-939.	3.1	44
95	Bullous Sarcoidosis. Chest, 1998, 114, 1474-1478.	0.8	43
96	Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings. Chest, 2006, 130, 855-862.	0.8	43
97	Advances in the diagnosis and treatment of sarcoidosis. F1000prime Reports, 2014, 6, 89.	5.9	43
98	Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. Chest, 2018, 153, 114-123.	0.8	43
99	COMPLICATIONS OF VIDEO ASSISTED THORACOSCOPIC LUNG BIOPSY IN PATIENTS WITH INTERSTITIAL LUNG DISEASE. Chest, 2005, 128, 168S.	0.8	41
100	The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology, 2008, 13, 97-102.	2.3	41
101	Relapses of sarcoidosis: what are they and can we predict who will get them?. European Respiratory Journal, 2014, 43, 337-339.	6.7	41
102	Interrelationship Between Sleep-Disordered Breathing and Sarcoidosis. Chest, 2015, 148, 1105-1114.	0.8	40
103	Primary Pulmonary Involvement of Fusarium solani in a Lung Transplant Recipient. Chest, 1997, 112, 1128-1130.	0.8	39
104	Clinical phenotypes in sarcoidosis. Current Opinion in Pulmonary Medicine, 2014, 20, 496-502.	2.6	39
105	The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. Respiratory Medicine, 2014, 108, 189-194.	2.9	39
106	A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 115-22.	0.2	38
107	Low Levels of NF- $\kappa$ B/p65 Mark Anergic CD4 + T Cells and Correlate with Disease Severity in Sarcoidosis. Vaccine Journal, 2011, 18, 223-234.	3.1	37
108	The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. Respiratory Medicine, 2015, 109, 557-564.	2.9	37

#	ARTICLE	IF	CITATIONS
109	The three tiers of screening for sarcoidosis organ involvement. <i>Respiratory Medicine</i> , 2016, 113, 42-49.	2.9	36
110	When the Game Changes. <i>Chest</i> , 2020, 158, 892-895.	0.8	36
111	Diagnostic Accuracy of Thoracic Ultrasonography to Differentiate Transudative From Exudative Pleural Effusion. <i>Chest</i> , 2020, 158, 692-697.	0.8	35
112	Successful Treatment of Widely Disseminated Acanthamoebiasis. <i>Southern Medical Journal</i> , 1999, 92, 55-57.	0.7	34
113	ICU admission body composition: skeletal muscle, bone, and fat effects on mortality and disability at hospital discharge—a prospective, cohort study. <i>Critical Care</i> , 2020, 24, 566.	5.8	34
114	Pneumoperitoneum to Treat Air Leaks and Spaces After a Lung Volume Reduction Operation. <i>Annals of Thoracic Surgery</i> , 1997, 64, 1803-1805.	1.3	32
115	A Case Report of a Dactylaria Fungal Infection in a Lung Transplant Patient. <i>Chest</i> , 2001, 119, 651-653.	0.8	32
116	Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. <i>Heart</i> , 2016, 102, 411-414.	2.9	32
117	Allergic Bronchopulmonary Aspergillosis After Infliximab Therapy for Sarcoidosis. <i>Chest</i> , 2009, 135, 1358-1359.	0.8	31
118	Impact of Systemic Corticosteroids on Healthcare Utilization in Patients With Sarcoidosis. <i>American Journal of the Medical Sciences</i> , 2011, 341, 196-201.	1.1	31
119	Quality of Life in Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 546-558.	2.1	31
120	Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. <i>Cancer</i> , 1987, 59, 807-810.	4.1	30
121	Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089.	2.6	30
122	The spectrum of biopsy sites for the diagnosis of sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005, 22, 139-46.	0.2	30
123	Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 865-871.	2.9	28
124	Clinical Manifestations, Radiographic Findings, Treatment Options, and Outcome in Sarcoidosis Patients with Upper Respiratory Tract Involvement. <i>Southern Medical Journal</i> , 2010, 103, 870-875.	0.7	26
125	A conceptual model of health-related quality of life in sarcoidosis. <i>Quality of Life Research</i> , 2014, 23, 89-101.	3.1	26
126	Pulmonary Physiologic Abnormalities Caused by Pleural Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1995, 16, 346-353.	2.1	25



#	ARTICLE	IF	CITATIONS
127	Pleural Effusion From Acute Lung Rejection. Chest, 1997, 111, 1128-1130.	0.8	25
128	Is There an Anatomic Explanation for Chest Pain in Patients With Pulmonary Sarcoidosis?. Southern Medical Journal, 1997, 90, 911-914.	0.7	25
129	The "Fairy Ring". Chest, 1999, 115, 275-276.	0.8	25
130	Range of the Fractional Weak Discrepancy Function. Order, 2006, 23, 51-63.	0.5	25
131	Valproic Acid-Induced Eosinophilic Pleural Effusion: A Case Report and Review of the Literature. American Journal of the Medical Sciences, 2007, 333, 290-292.	1.1	25
132	Concomitant sarcoidosis and a connective tissue disease: Review of the clinical findings and postulations concerning their association. Respiratory Medicine, 2013, 107, 1453-1459.	2.9	25
133	Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. Expert Review of Respiratory Medicine, 2017, 11, 111-118.	2.5	25
134	Noninvasive Aspergillus Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 203-219.	2.1	24
135	Distinguishing Asthma from Sarcoidosis: An Approach to a Problem that is not Always Solvable. Journal of Asthma, 2013, 50, 1-6.	1.7	24
136	The diagnosis of sarcoidosis. Current Opinion in Pulmonary Medicine, 2019, 25, 484-496.	2.6	24
137	The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. Respiratory Medicine, 2021, 187, 106564.	2.9	24
138	Sarcoidosis Associated With an Elevated Serum CA 125 Level: Description of a Case and a Review of the Literature. American Journal of the Medical Sciences, 2007, 334, 441-443.	1.1	23
139	Intracavitary voriconazole for the treatment of hemoptysis complicating <i>Pseudallescheria angusta</i> pulmonary mycetomas in fibrocystic sarcoidosis. Medical Mycology, 2011, 49, 198-201.	0.7	23
140	Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. Chest, 2021, 159, 1902-1912.	0.8	23
141	Current pharmacotherapy of allergic bronchopulmonary aspergillosis. Expert Opinion on Pharmacotherapy, 2001, 2, 1065-1071.	1.8	22
142	How are cancer and connective tissue diseases related to sarcoidosis?. Current Opinion in Pulmonary Medicine, 2015, 21, 517-524.	2.6	22
143	Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF- $\kappa$ B/cyclin D1 pathway. Nature Communications, 2020, 11, 3527.	12.8	22
144	The Etiologic Agent of Sarcoidosis. Chest, 2003, 124, 6-8.	0.8	21

#	ARTICLE	IF	CITATIONS
145	Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R250-R257.	1.8	21
146	The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 280-282.	0.2	21
147	Management of Advanced Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 495-506.	5.6	21
148	Quality of Life Assessment in Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 739-750.	2.1	20
149	The Relationship of Pleural Manometry With Postthoracentesis Chest Radiographic Findings in Malignant Pleural Effusion. Chest, 2020, 157, 421-426.	0.8	20
150	Granulomatous Sarcoidosis Mimics. Frontiers in Medicine, 2021, 8, 680989.	2.6	20
151	How many organs need to be involved to diagnose sarcoidosis?: An unanswered question that, hopefully, will become irrelevant. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 6-7.	0.2	20
152	Quality of life evaluation in sarcoidosis: current status and future directions. Current Opinion in Pulmonary Medicine, 2008, 14, 470-477.	2.6	19
153	Sarcoidosis Presenting as Bilateral Vocal Cord Paralysis From Bilateral Compression of the Recurrent Laryngeal Nerves From Thoracic Adenopathy. Journal of Voice, 2009, 23, 631-634.	1.5	18
154	Successful Treatment of Lupus Pernio With Adalimumab. Archives of Dermatology, 2011, 147, 1332.	1.4	18
155	Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome. Microbiology Spectrum, 2017, 5, .	3.0	18
156	Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, e2020009.	0.2	18
157	The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 235.	0.2	18
158	Mycobacterium scrofulaceum Infection Presenting as Lung Nodules in a Heart Transplant Recipient. Chest, 1994, 106, 1918-1920.	0.8	17
159	Carbon Nanotubes and Chronic Granulomatous Disease. Nanomaterials, 2014, 4, 508-521.	4.1	17
160	The role of serum amyloid A staining of granulomatous tissues for the diagnosis of sarcoidosis. Respiratory Medicine, 2017, 126, 1-8.	2.9	17
161	The Management of Sarcoidosis by the Primary Care Physician. American Journal of Medicine, 2007, 120, 403-407.	1.5	16
162	Small fiber neuropathy in sarcoidosis: Something beneath the surface. Respiratory Medicine, 2011, 105, 1-2.	2.9	16

#	ARTICLE	IF	CITATIONS
163	Clinical aspects of portopulmonary hypertension. <i>Respiratory Medicine</i> , 2014, 108, 943-954.	2.9	16
164	Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. <i>Quality of Life Research</i> , 2014, 23, 1301-1313.	3.1	16
165	Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. <i>Respiratory Medicine</i> , 2019, 152, 14-19.	2.9	16
166	Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021, 18, 477-485.	3.2	16
167	COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 2021, 8, 672028.	2.6	16
168	Pneumothorax and Bronchopleural Fistula During Treatment of Allergic Bronchopulmonary Aspergillosis. <i>Southern Medical Journal</i> , 1993, 86, 1061-1063.	0.7	15
169	Refractory Hypotension Associated With Hypocalcemia and Renal Disease. <i>American Journal of Kidney Diseases</i> , 1994, 23, 430-432.	1.9	15
170	Highly Active Antiretroviral Therapy for HIV With Tuberculosis. <i>Chest</i> , 2002, 122, 399-400.	0.8	15
171	Pleural Effusion Caused by Trapped Lung. <i>Southern Medical Journal</i> , 2003, 96, 510-511.	0.7	15
172	The Assessment of Cough in a Sarcoidosis Clinic Using a Validated instrument and a Visual Analog Scale. <i>Lung</i> , 2017, 195, 587-594.	3.3	15
173	Patient perspectives in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 478-483.	2.6	15
174	Cardiac Sarcoidosis. <i>Chest</i> , 2005, 128, 3-6.	0.8	14
175	A proposed solution to the clinical assessment of sarcoidosis: The sarcoidosis three-dimensional assessment instrument (STAI). <i>Medical Hypotheses</i> , 2007, 68, 1080-1087.	1.5	14
176	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	4.8	14
177	Screening sarcoidosis patients for cardiac sarcoidosis: What the data really show. <i>Respiratory Medicine</i> , 2019, 154, 155-157.	2.9	13
178	Chylothorax in a Patient With AIDS and Kaposi's Sarcoma. <i>Southern Medical Journal</i> , 1990, 83, 322-324.	0.7	12
179	Bird-Years as Well as Pack-Years. <i>Chest</i> , 2004, 125, 353-354.	0.8	12
180	The pressure-dependent air leak after partial lung resection. <i>Thorax</i> , 2017, 72, 290-291.	5.6	12

#	ARTICLE	IF	CITATIONS
181	The Diagnosis of Sarcoidosis. Chest, 2018, 154, 1006-1007.	0.8	12
182	Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels. Translational Research, 2021, 230, 5-20.	5.0	12
183	Mediastinal Lymphadenopathy in Patients Undergoing Cardiac Transplant Evaluation. Chest, 2011, 139, 1451-1457.	0.8	11
184	Worsening of pulmonary sarcoidosis. Current Opinion in Pulmonary Medicine, 2014, 20, 508-516.	2.6	11
185	Granulomatous lung disease: clinical aspects. Expert Review of Respiratory Medicine, 2020, 14, 1045-1063.	2.5	11
186	Therapeutic strategies for pulmonary sarcoidosis. Expert Review of Respiratory Medicine, 2020, 14, 391-403.	2.5	11
187	Coexistent Takayasu arteritis and sarcoidosis: a case report and review of the literature. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 311-317.	0.2	11
188	Status Asthmaticus With Acute Decompensation With Therapy in a 27-Year-Old Woman. Chest, 1995, 107, 563-565.	0.8	10
189	Patient-Reported Outcome Measures for Sleep Disorders and Related Problems. Chest, 2013, 143, 1809-1818.	0.8	10
190	Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis. Nuclear Medicine Communications, 2016, 37, 273-277.	1.1	10
191	Sevoflurane Induced Diffuse Alveolar Hemorrhage in a young patient. Respiratory Medicine Case Reports, 2017, 20, 14-15.	0.4	10
192	Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument. JAMA Dermatology, 2020, 156, 98.	4.1	10
193	Association between Drainage-Dependent Prolonged Air Leak after Partial Lung Resection and Clinical Outcomes: A Prospective Cohort Study. Annals of the American Thoracic Society, 2022, 19, 389-398.	3.2	10
194	Treatment of a Solitary Pulmonary Sarcoidosis Mass by CT-Guided Direct Intralesional Injection of Corticosteroid. Chest, 2001, 120, 316-317.	0.8	9
195	Reply to: Monogenic early-onset sarcoidosis is no longer a variant of "idiopathic" sarcoidosis. Journal of the American Academy of Dermatology, 2013, 69, 165.	1.2	9
196	The value of sound waves and pleural manometry in diagnosing a pleural effusion with the dual diagnosis. Thorax, 2016, 71, 1064-1065.	5.6	9
197	A sarcoidosis clinician's perspective of MHC functional elements outside the antigen binding site. Human Immunology, 2019, 80, 85-89.	2.4	9
198	Screening Sarcoidosis Patients for Occult Disease. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 741-757.	2.1	9

#	ARTICLE	IF	CITATIONS
199	Corticosteroid refractory sarcoidosis. <i>Respiratory Medicine</i> , 2020, 171, 106081.	2.9	9
200	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2022, 191, 106436.	2.9	9
201	High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 136-141.	0.2	9
202	Vaginal Involvement in a Patient With Sarcoidosis. <i>Chest</i> , 2010, 137, 455-456.	0.8	8
203	Rapid Development of Sarcoid Tenosynovitis. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 201-203.	0.9	8
204	A Delphi Study of Pharmacotherapy for Noncystic Fibrosis Bronchiectasis. <i>American Journal of the Medical Sciences</i> , 2014, 348, 387-393.	1.1	8
205	The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials. <i>Respiratory Medicine</i> , 2019, 149, 23-27.	2.9	8
206	Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. <i>F1000Research</i> , 2019, 8, 2149.	1.6	8
207	Staple Metalloptysis After Lung Resection for Mycetoma: A Case Report and a Review of the Literature. <i>American Journal of the Medical Sciences</i> , 2008, 336, 365-367.	1.1	7
208	Endpoints in sarcoidosis: More like IPF or asthma?. <i>Respiratory Medicine</i> , 2018, 138, S3-S4.	2.9	7
209	The epidemic of drug-induced sarcoidosis-like reactions: a side effect that we can live with. <i>Journal of Internal Medicine</i> , 2020, 288, 373-375.	6.0	7
210	Sarcoidosis associated pleural effusion: Clinical aspects. <i>Respiratory Medicine</i> , 2022, 191, 106723.	2.9	7
211	Origin of Pleural Cells After Lung Transplantation*. <i>Chest</i> , 1997, 112, 426-429.	0.8	6
212	ASSESSMENT OF INFlixIMAB EFFICACY IN EXTRAPULMONARY SARCOIDOSIS USING A NOVEL ASSESSMENT TOOL: RESULTS FROM A RANDOMIZED TRIAL. <i>Chest</i> , 2005, 128, 202S.	0.8	6
213	Readdressing the entity of exercise pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2017, 124, 65-71.	2.9	6
214	Blastomycosis in the Capital District of New York State: A Newly Identified Emerging Endemic Area. <i>American Journal of Medicine</i> , 2021, 134, e101-e108.	1.5	6
215	Quality of Life and Physical Activity in 629 Individuals With Sarcoidosis: Prospective, Cross-sectional Study Using Smartphones (Sarcoidosis App). <i>JMIR MHealth and UHealth</i> , 2022, 10, e38331.	3.7	6
216	Unusual Presentations of Pulmonary Sarcoidosis: Cases from the Medical University of South Carolina. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 075-082.	2.1	5

#	ARTICLE	IF	CITATIONS
217	Assessment of Mediastinal Lymph Node Size in Pneumococcal Pneumonia with Bacteremia. Lung, 2018, 196, 43-48.	3.3	5
218	Rare case of parathyroid gland sarcoidosis presenting with hypercalcaemia. BMJ Case Reports, 2019, 12, e230598.	0.5	5
219	Inflammatory Pathways in Sarcoidosis. Advances in Experimental Medicine and Biology, 2021, 1304, 39-52.	1.6	5
220	Management of immunosuppressants in the era of coronavirus disease-2019. Current Opinion in Pulmonary Medicine, 2021, 27, 176-183.	2.6	5
221	Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication. Respiratory Medicine, 2021, 180, 106371.	2.9	5
222	The Relationship of Obesity and OSA to the Development of Sarcoidosis. Chest, 2022, 162, 1086-1092.	0.8	5
223	Pneumocystis carinii Pneumonia Manifested as Hilar Mass and Cavitory Lesion: An Atypical Presentation in a Patient Receiving Aerosolized Pentamidine Prophylaxis. Southern Medical Journal, 1990, 83, 1309-1312.	0.7	4
224	Lupus Pernio or Chilblain Lupus?: Response. Chest, 2009, 136, 947.	0.8	4
225	Lung Transplantation for Sarcoidosis. Lung Biology in Health and Disease, 2005, , 745-767.	0.1	4
226	Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021035.	0.2	4
227	Granulomatosis and Polyangitis Followed by Alveolar Proteinosis in a 32-Year-Old Woman. Chest, 2012, 141, 1359-1360.	0.8	3
228	Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism. Case Reports in Medicine, 2013, 2013, 1-2.	0.7	3
229	Reply to Bauer and Goff. Clinical Infectious Diseases, 2015, 61, 487-488.	5.8	3
230	Pasteurella multocida pleural effusion: A case report and review of literature. Respiratory Medicine Case Reports, 2016, 19, 68-70.	0.4	3
231	Causes of Poor Medication Adherence in Sarcoidosis. Chest, 2020, 158, 17-18.	0.8	3
232	Corticosteroid-Sparing Drugs in Sarcoidosis: How Should We Assess Them?. Lung, 2021, 199, 85-86.	3.3	3
233	A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist. Journal of Clinical Medicine, 2021, 10, 2857.	2.4	3
234	The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice. Current Opinion in Pulmonary Medicine, 2022, 28, 451-460.	2.6	3

#	ARTICLE	IF	CITATIONS
235	A 74-year-old Man With Chronic Lymphocytic Leukemia, Cough, and a Lung Mass. <i>Chest</i> , 1999, 116, 1798-1801.	0.8	2
236	Pharyngitis, Splenomegaly, and Hilar and Peripheral Adenopathy in a 29-Year-Old Man With Acute Hypoxic Respiratory Failure. <i>Chest</i> , 2001, 119, 1586-1589.	0.8	2
237	Diagnosis and treatment of allergic bronchopulmonary aspergillosis. <i>Current Fungal Infection Reports</i> , 2008, 2, 199-205.	2.6	2
238	Tuberculous mediastinal lymphadenitis that evolved into pulmonary tuberculosis following transbronchial needle aspiration. <i>Respirology</i> , 2010, 15, 1140-1141.	2.3	2
239	Sarcoidosis: Lost in translation. <i>Respirology</i> , 2011, 16, 384-385.	2.3	2
240	Chronic Hypoxemia and Paraganglioma: A Rare Case and Discussion of Potential Mechanisms. <i>American Journal of the Medical Sciences</i> , 2014, 348, 528-529.	1.1	2
241	Determining the cause of pulmonary granulomas: A multidimensional process. <i>Respirology</i> , 2015, 20, 5-6.	2.3	2
242	Effect of SSRIs and SNRIs on Nocturnal Urinary Frequency. <i>Annals of Pharmacotherapy</i> , 2016, 50, 471-474.	1.9	2
243	Emerging and potential treatment options for sarcoidosis. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 17-33.	0.8	2
244	The time bomb of isolated cardiac sarcoidosis: Is it ticking?. <i>International Journal of Cardiology</i> , 2022, 347, 62-63.	1.7	2
245	The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819.	2.9	2
246	Tissue verification of stage I sarcoidosis: the question is if, not how. <i>Chest</i> , 2008, 133, 1529-1530.	0.8	2
247	Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021034.	0.2	2
248	Dysphagia From Thoracostomy Tube Compression of the Esophagus After Single Lung Transplantation. <i>Southern Medical Journal</i> , 1996, 89, 249-250.	0.7	1
249	Concomitant Acute Sinusitis and Acute Lung Rejection. <i>Southern Medical Journal</i> , 2000, 93, 223-225.	0.7	1
250	A Neutropenic Patient With Rapidly Progressive Lung Lesion. <i>Chest</i> , 2004, 126, 1364-1367.	0.8	1
251	Lupus Pernio Activity and Severity Index (LuPASI) Score in Sarcoidosis Patients. <i>Chest</i> , 2004, 126, 891S.	0.8	1
252	Trouble Below the Surface. <i>American Journal of Medicine</i> , 2006, 119, 828-831.	1.5	1

#	ARTICLE	IF	CITATIONS
253	SARCOIDOSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SAPAH): CHARACTERISTICS OF PATIENTS ENROLLED IN A PROSPECTIVE, OPEN LABEL TRIAL OF INHALED ILOPROST. Chest, 2007, 132, 482A.	0.8	1
254	Intracavitary Voriconazole For Symptomatic Pseudallescheria Boydii Pulmonary Mycetomas In A Patient With Fibrocystic Sarcoidosis. , 2010, , .		1
255	Intracavitary Amphotericin B For Pulmonary Aspergilloma Complicated By Serious Hemoptysis In Fibrocystic Sarcoidosis. , 2010, , .		1
256	A 23-Year-Old Man With Recurrent Hemoptysis. Chest, 2015, 148, e152-e155.	0.8	1
257	A Bare-Bones Approach. New England Journal of Medicine, 2017, 376, 1371-1376.	27.0	1
258	A necrotic tonsillar lesion: An unusual presentation of disseminated histoplasmosis. Respiratory Medicine Case Reports, 2017, 22, 44-46.	0.4	1
259	Respiratory Medicine: Focus on Sarcoidosis: Editor's welcome. Respiratory Medicine, 2018, 138, S1-S2.	2.9	1
260	Considerations regarding sarcoidosis in the bariatric surgical patient. Surgery for Obesity and Related Diseases, 2018, 14, 219-224.	1.2	1
261	Monitoring cardiac sarcoidosis: The next frontier. Respiratory Medicine, 2018, 144, S5-S6.	2.9	1
262	Parasarcoidosis Syndromes. , 2019, , 167-177.		1
263	Assessing the reliability of obstructive sleep apnea screening instruments in isolation or in combination. Respiratory Medicine: X, 2020, 2, 100019.	1.4	1
264	RESPONDER ANALYSES IN PATIENTS RECEIVING INFLIXIMAB FOR CHRONIC SARCOIDOSIS WITH PULMONARY INVOLVEMENT. Chest, 2005, 128, 316S.	0.8	1
265	Acute Pulmonary Exacerbation of Sarcoidosis. , 2014, , 65-78.		1
266	Proteinuria in sarcoidosis: Prevalence and risk factors in a consecutive outpatient cohort. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 142-148.	0.2	1
267	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.	0.2	1
268	The ability to predict the clinical course of pulmonary sarcoidosis from data that is right in front of us. Jornal Brasileiro De Pneumologia, 2022, 48, e20220012.	0.7	1
269	Estimation of Auto-PEEP. Chest, 1991, 99, 519.	0.8	0
270	It's Not "Just a Virus" Anymore. Chest, 1998, 113, 859-860.	0.8	0



#	ARTICLE	IF	CITATIONS
271	DIAGNOSIS OF PULMONARY SARCOIDOSIS USING ENDOBRONCHIAL ULTRASONOGRAPHY WITH TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) AS A PRIMARY DIAGNOSTIC MODALITY. Chest, 2006, 130, 111S.	0.8	0
272	Sarcoidosis: Evolving Concepts and Controversies. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 001-002.	2.1	0
273	Dyspnea Originating Far From the Heart and Lung. Chest, 2015, 148, 860A.	0.8	0
274	Serum Amyloid a Immunostaining of Granulomatous Tissue as a Novel Diagnostic Test for Sarcoidosis. Chest, 2016, 150, 788A.	0.8	0
275	Allergic bronchopulmonary aspergillosis: what's known and what's new. Current Pulmonology Reports, 2016, 5, 177-183.	1.3	0
276	Predictors of Cardiac Decompensation in Patients With Cardiac Sarcoidosis Undergoing De-escalation of Treatment. Chest, 2017, 152, A73.	0.8	0
277	Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome. , 0, , 637-652.		0
278	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. Open Forum Infectious Diseases, 2017, 4, S52-S52.	0.9	0
279	Sarcoidosis: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 605-606.	2.1	0
280	Response. Chest, 2020, 158, 1783-1784.	0.8	0
281	The Reply. American Journal of Medicine, 2020, 133, e206-e207.	1.5	0
282	Editorial: Novel Insights Into the Immunology of Pulmonary Granulomatous Diseases. Frontiers in Immunology, 2020, 11, 633103.	4.8	0
283	Response. Chest, 2021, 159, 1307-1308.	0.8	0
284	The Treatment of ABPA. , 2009, , 747-759.		0
285	The Diagnosis of Sarcoidosis. , 2014, , 1-18.		0
286	Physician Mistrust and Discrimination in Sarcoidosis: It's Real and It's Prevalent. Annals of the American Thoracic Society, 2021, 18, 1781-1783.	3.2	0
287	Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 192-197.	0.2	0
288	The manifestations of rare organ sarcoidosis. , 2022, , 295-315.		0

#	ARTICLE	IF	CITATIONS
289	Quality-of-life assessment in patients with sarcoidosis. , 2022, , 337-349.		0